Next Article in Journal
Finding New Molecular Targets of Familiar Natural Products Using In Silico Target Prediction
Next Article in Special Issue
Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa
Previous Article in Journal
Transcriptomic Profiling for the Autophagy Pathway in Colorectal Cancer
Previous Article in Special Issue
The Role and Impact of Extracellular Vesicles in the Modulation and Delivery of Cytokines during Autoimmunity
Open AccessReview

Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases

1
Rheumatology & Immuno-Mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur). SERGAS-UVIGO, 36201 Vigo, Spain
2
Rheumatology Department, University Hospital Complex of Vigo, 36201 Vigo, Spain
*
Author to whom correspondence should be addressed.
These authors equally contributed to this work.
Int. J. Mol. Sci. 2020, 21(19), 7100; https://doi.org/10.3390/ijms21197100
Received: 31 August 2020 / Revised: 17 September 2020 / Accepted: 24 September 2020 / Published: 26 September 2020
Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option. View Full-Text
Keywords: Interleukin-17; systemic rheumatic diseases; T helper 17 cells; Sjögren’s syndrome; systemic lupus erythematosus; systemic sclerosis; therapeutic target Interleukin-17; systemic rheumatic diseases; T helper 17 cells; Sjögren’s syndrome; systemic lupus erythematosus; systemic sclerosis; therapeutic target
Show Figures

Graphical abstract

MDPI and ACS Style

Rafael-Vidal, C.; Pérez, N.; Altabás, I.; Garcia, S.; Pego-Reigosa, J.M. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. Int. J. Mol. Sci. 2020, 21, 7100. https://doi.org/10.3390/ijms21197100

AMA Style

Rafael-Vidal C, Pérez N, Altabás I, Garcia S, Pego-Reigosa JM. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. International Journal of Molecular Sciences. 2020; 21(19):7100. https://doi.org/10.3390/ijms21197100

Chicago/Turabian Style

Rafael-Vidal, Carlos; Pérez, Nair; Altabás, Irene; Garcia, Samuel; Pego-Reigosa, Jose M. 2020. "Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases" Int. J. Mol. Sci. 21, no. 19: 7100. https://doi.org/10.3390/ijms21197100

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop